Response Rates
| Autor: | Xavier Pivot, Cristian Villanueva, Fernando Bazan, Antoine Thierry-Vuillemin |
|---|---|
| Přispěvatelé: | Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Saas, Philippe |
| Rok vydání: | 2009 |
| Předmět: |
MESH: Forecasting
MESH: Remission Induction Cancer Research Pathology medicine.medical_specialty Phase iii trials [SDV.IMM] Life Sciences [q-bio]/Immunology Antineoplastic Agents World Health Organization MESH: World Health Organization World health 03 medical and health sciences Clinical Trials Phase II as Topic 0302 clinical medicine MESH: Practice Guidelines as Topic Neoplasms Humans Medicine MESH: Neoplasms MESH: Treatment Outcome 030304 developmental biology 0303 health sciences MESH: Humans business.industry Remission Induction SIGNAL (programming language) Tumor shrinkage 3. Good health Clinical trial Response assessment Treatment Outcome Oncology Risk analysis (engineering) Response Evaluation Criteria in Solid Tumors 030220 oncology & carcinogenesis Practice Guidelines as Topic MESH: Antineoplastic Agents [SDV.IMM]Life Sciences [q-bio]/Immunology Metric (unit) business MESH: Clinical Trials Phase II as Topic Forecasting |
| Zdroj: | Cancer Journal Cancer Journal, Lippincott, Williams & Wilkins, 2009, 15 (5), pp.361-5. ⟨10.1097/PPO.0b013e3181bd045f⟩ |
| ISSN: | 1528-9117 1540-336X |
| DOI: | 10.1097/ppo.0b013e3181bd045f |
| Popis: | International audience; A main criterion to identify activity in phase II studies is the response rates achieved in a well-defined subset of patients. The response could be defined as a measure of tumor shrinkage. For 30 years, metric methods have been used to assess this response. The World Health Organization was the first organization to propose a unified definition for response status. Over time, the latter evolved and 10 years ago an international consensus panel proposed the Response Evaluation Criteria in Solid Tumors criteria. Although these guidelines for response assessment have limitations and biases, they have nevertheless been proven useful and advantageous. This article reviews those criteria and describes their use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|